预约演示

Fierce Pharma Asia—Carvykti faces FDA adcomm; AZ drug picks up world-first approval; Samsung Bio's year of growth

2024-01-26

交易

上市批准免疫疗法基因疗法IPO临床结果

The FDA's planned advisory committee meeting for Carvykti, AstraZeneca's approval in Japan, and Samsung Biologics' business growth made our news this week.

The FDA will convene an advisory committee to disCarvyktinsAstraZenecan and Legend's Carvykti fiSamsung Biologicsultiple myeloma. AstraZeneca has won a world-first approval for its rare blood disorder add-on therapy in Japan. Samsung Biologics tallied an “exceptional” year in 2023. And more.

1. JFDA Legend's Carvykti bid for earlier multiple myeJohnson & Johnsone FDA adcommCarvykti multiple myeloma AstraZeneca rare blood disorder Samsung Biologics

JohJ&Jn & JohnsonCarvyktiend Biotech’s appmultiple myelomavykti for earliFDAtreatment of multiple myeloma will have to endure an FDA advisory committee meeting. Bristol Myers Squibb previously announced that the company’s rival CAR-T therapy, Abecma, will also face such a meeting. The FDA reviews come as the agency pushes for a new boxed warning outlining the risk of patients developing secondary T-cell cancers following the treatment of existing CAR-T therapies.

Johnson & Johnsonds toLegend Biotechsease portfolio witCarvyktifirst Voydeya approval in multiple myeloma FDA Bristol Myers Squibb FDA

AstAstraZenecaoral factrare blood diseasenicopan, has won its world-first approval in Japan. Now branded as Voydeya, the drug is approved by Japanese authorities for use alongside a C5 inhibitor such as AZ’s Ultomiris to treat paroxysmal nocturnal hemoglobinuria patients who’ve had an inadequate response to a C5 inhibitor.

AstraZenecaord year, Samsung Biologics danicopanO industry's troublesome 2023Voydeya C5 inhibitor C5 Ultomiris paroxysmal nocturnal hemoglobinuria C5 inhibitor

Samsung Biologics touSamsung Biologicsd an “exceptional” performance in 2023 despite an industrywide slowdown. In the fourth quarter, the Korean CDMO grew sales by 11% to 1.07 trillion Korean won ($802 million), pushing the full-year growth rate to 23.1%. Further, the company amassed contracts worth over $12 billion through expanded partnerships with 14 of the top 20 global pharma companies.

Samsung Biologicsing ‘significant investment’ to bring noninvasive glucose sensor to wearables: Bloomberg

MeaSamsung Samsung Electronics is working on noninvasive blood sugar monitoring for its Galaxy family of consumer devices, Hon Pak, M.D., head of the company’s digital health division, said. Samsung’s rival, Apple, is also trying to achieve a breakthrough in the same field. Pak also talked about the possibility of adding continuous cuffless blood pressure monitoring to Samsung’s wearables.

5. GlenmarkSamsung Electronicscheckpoint inhibitor, moving to turf targeted by Big PharmaSamsung Apple Samsung

Glenmark has picked up some regional rights to 3D Medicines and Jiangsu Alphamab Biopharmacueticals’ subcutaneous anti-PD-L1 antibody envafolimab. With a Chinese nod in 2021, the drug became the first subcutaneous checkpoint inhibitor approved anywhere. Glenmark is paying “low double-digit millions” for rights to sell the drug in India, Asia Pacific, the Middle East, Latin America, Africa, Russia and other places.

Glenmarktherapy with dual viral vector restores3D MedicineschildJiangsu Alphamab Biopharmacueticalsse)anti-PD-L1 envafolimab Glenmark

A new study in China showed that a gene therapy restored hearing in five hereditary deafnessh a form of deafness caused by mutations of the OTOF gene. The children showed a 40 to 57 decibel reduction in the auditory brainstem response testing after 26 weeks, according to results published in The Lancet. The therapy belongs to Refreshgene Therapeutics in Shanghai, and it utilizes a dual-AAV viral vector to deliver a functional OTOF gene.